Futura Medical has moved its formal sale process into a more active phase. In an update on 8 October 2026, the company said it had begun circulating an information memorandum to interested parties and expected non-binding offers over the following four weeks. It also announced a change in its finance leadership.

What the company does

Futura Medical is a UK healthcare company developing and commercialising products in sexual health. Its best-known product is MED3000, sold under the Eroxon brand. Its pipeline also includes WSD4000, which the company has said could achieve estimated peak annual consumer sales of more than US$400 million. Headlines published during 2026 show steady activity around both programmes, including positive home-use test results for Eroxon and a stronger Eroxon "Intense" variant in March, highly positive data from WSD4000 studies in June, and an EU market launch clearance at the end of July.

Latest developments

On 3 September 2026, Futura announced a fundraise alongside the launch of a formal sale process and a wider mergers and acquisitions process. The board said, in effect, that the market valuation did not reflect the strategic potential of its portfolio, and that it would explore a possible sale of the company or its assets.

The October update said the information memorandum was now with interested parties. The company stressed that there is no certainty a transaction will result, and it did not name any potential bidders or terms. Since the process began, the company's listing has been dominated by Form 8 disclosures under the Takeover Code, which are required from parties holding significant interests during an offer period.

On the board, Angela Hildreth, finance director and chief operating officer, was due to step down from her executive role on 13 November 2026 and stay on as a non-executive director to provide continuity. Madelein Kennedy was appointed interim chief financial officer on a consultancy basis from 12 October 2026.

Financial and Dividend picture

The September fundraise raised about £1.6 million through a placing and subscription at 0.2 pence per share, with a separate retail offer of up to £150,000. The company said the proceeds would extend its cash runway into February 2027, which gives the sale process a defined but limited window. Futura published unaudited interim results on 1 September 2026, but those figures were not available in the material reviewed for this article. The company does not pay a dividend.

Sector and index context

Futura is among the smaller healthcare names on the FTSE AIM All Share Index. Consumer health and over-the-counter products can attract larger strategic buyers that have the distribution scale that small developers lack, which helps explain why many AIM-quoted life sciences companies consider sales or licensing deals. However, sale processes on AIM do not always end in a transaction, and outcomes can range from a full takeover to the sale of individual assets.

Key risks

The main risk is that the sale process fails to produce an acceptable offer, leaving the company to seek more funding before its runway ends in early 2027. The very low placing price points to significant past dilution. Intellectual property is a further consideration: in July 2026 the company announced a European Patent opposition relating to MED3000. Commercial uptake of Eroxon and the development path for WSD4000 also remain uncertain.

What to watch next

Investors will be watching for news on non-binding offers and whether any party moves to a firm bid or asset purchase. Further Takeover Code disclosures, updates on Eroxon in Europe and progress with WSD4000 will also be closely followed.